Aileron therapeutics inc (ALRN)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Revenue

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

17,558

17,663

16,915

16,761

17,776

18,448

18,798

18,302

16,143

14,239

13,020

11,800

10,725

10,276

0

0

0

General and administrative

11,961

12,293

12,675

12,412

13,676

13,454

13,163

12,587

10,039

8,769

7,395

6,421

8,094

7,893

0

0

0

Total operating expenses

29,519

29,956

29,590

29,173

31,452

31,902

31,961

30,889

26,182

23,008

20,415

18,221

18,819

18,169

0

0

0

Loss from operations

-29,519

-29,956

-29,590

-29,173

-31,452

-31,902

-31,961

-30,889

-26,182

-23,008

-20,415

-18,221

-18,819

-18,169

0

0

0

Gain on sale of property and equipment

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

548

586

422

320

280

355

583

686

547

404

234

77

64

46

0

0

0

Net loss

-28,905

-29,370

-29,168

-28,853

-31,172

-31,547

-31,378

-30,203

-25,635

-22,604

-20,181

-18,144

-18,755

-18,123

0

0

0

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

41

60

79

77

75

0

0

0

Net loss

-

-

-

-

-

-

-

-

-

-22,645

-20,241

-18,223

-18,832

-18,198

0

0

0

Net loss per share — basic and diluted

-0.24

-0.26

-0.28

-0.26

-0.49

-0.48

-0.50

-0.64

-0.52

-0.47

-0.45

-10.98

-10.58

-10.31

-9.84

-12.95

-9.25

Weighted average common shares outstanding—basic and diluted

27,810

27,810

27,810

27,526

14,816

14,745

14,737

14,737

14,732

14,720

13,939

450

432

432

430

428

426

Comprehensive loss:
Net loss

-28,905

-29,370

-29,168

-28,853

-31,172

-31,547

-31,378

-30,203

-25,635

-22,604

-20,181

-18,144

-18,755

-18,123

0

0

0

Other comprehensive gain (loss):
Unrealized gain (loss) on investments, net of tax of $0

-1

12

20

36

50

28

3

-12

0

0

0

-

-

0

0

0

0

Total other comprehensive gain (loss)

-1

12

20

36

50

28

3

-12

0

0

0

-

-

0

0

0

0

Total comprehensive loss

-28,906

-29,358

-29,148

-28,817

-31,122

-31,519

-31,375

-30,215

-25,685

-22,637

-20,186

-18,146

-18,762

-18,123

0

0

0